A Study to Assess the Pharmacokinetic Profile of an Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8mg/2mg Capsules Relative to the Pharmacokinetic Profile of Suboxone (Buprenorphine HCl/Naloxone HCl 8mg/2mg Sublingual Tablets).

Trial Profile

A Study to Assess the Pharmacokinetic Profile of an Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8mg/2mg Capsules Relative to the Pharmacokinetic Profile of Suboxone (Buprenorphine HCl/Naloxone HCl 8mg/2mg Sublingual Tablets).

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine/naloxone
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors Nanotherapeutics; Ology Bioservices
  • Most Recent Events

    • 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
    • 28 Jun 2017 Last checked against ClinicalTrials.gov record.
    • 10 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top